RE: post police30 Dec 2018 06:28
Not wanting to throw water on the fire, but correspondence I received on the 24th indicated that an articles had already been included.
Subject: bioworld
Regent Pacific Group Ltd., of Hong Kong, said it is licensing commercial rights for its premature ejaculation therapy Fortacin (lidocaine + prilocaine) in numerous Asian territories excluding China to Orient Europharma Co Ltd. The deal, in addition to an earlier licensing agreement Regent made with China-based Shanghai Fosun Pharmaceutical Group Co. Ltd. subsidiary Wanbang Pharma for China rights, “should open the door to Asia-wide availability [of Fortacin] in the coming years, with first roll-out scheduled in Hong Kong and Macau in 2019, and further launches planned for Taiwan and other countries in Southeast Asia in 2020,” said Regent Pacific’s CEO.
And no +ve impact, just a subsequent slide. But then again, if one blinked, one would have missed it....LOL